Cargando…

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

BACKGROUND: The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. METHODS: This is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahma, Osama E, Tyan, Kevin, Giobbie-Hurder, Anita, Brohl, Andrew S, Bedard, Philippe L, Renouf, Daniel J, Sharon, Elad, Streicher, Howard, Hathaway, Emma, Cunningham, Rachel, Manos, Michael, Severgnini, Mariano, Rodig, Scott, Stephen Hodi, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915279/ https://www.ncbi.nlm.nih.gov/pubmed/35264434 http://dx.doi.org/10.1136/jitc-2021-003569

Ejemplares similares

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

Ziv-aflibercept in metastatic colorectal cancer
por: Patel, Anuj, et al.
Publicado: (2013)

Ziv-Aflibercept Use in Metastatic Colorectal Cancer
por: Rodriguez, Mabel
Publicado: (2013)

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits
por: Ramon, Dan, et al.
Publicado: (2018)

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
por: Braimah, Imoro Z, et al.
Publicado: (2019)

Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
por: Nawar, Amin E., et al.
Publicado: (2020)

The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration
por: Juhong, Jakkrit, et al.
Publicado: (2022)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases
por: HodjatJalali, Kamran, et al.
Publicado: (2017)

Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation
por: Hermosilla, Jesús, et al.
Publicado: (2020)

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
por: de Lima Farah, Julia, et al.
Publicado: (2018)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
por: Singh, Sumit Randhir, et al.
Publicado: (2018)

Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients
por: Lu, Chieh-Sheng, et al.
Publicado: (2016)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
por: Strickler, John H., et al.
Publicado: (2019)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
por: Eldeeb, Mohab, et al.
Publicado: (2017)

A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas
por: Meehan, Robert, et al.
Publicado: (2018)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy – short term study
por: Mishra, Sai B., et al.
Publicado: (2022)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
por: Nawar, Amin E., et al.
Publicado: (2022)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Sen, Alok, et al.
Publicado: (2015)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
por: Anshuman, Kumar, et al.
Publicado: (2019)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour, Ahmad M, et al.
Publicado: (2019)

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
por: Moradian, Siamak, et al.
Publicado: (2023)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane
por: Radke, Nishant, et al.
Publicado: (2017)

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6u38fb0k47u7c4s1o8em0pt179